Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 6/20 | 0.61 |
| ▸ | P2RX1 | P51575 | 4/20 | 0.61 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.61 |
| ▸ | P2RX4 | Q99571 | 5/20 | 0.59 |
| ▸ | P2RY1 | P47900 | 4/20 | 0.59 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.59 |
| ▸ | SRC | P12931 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.57 |
| ▸ | MACROD2 | A1Z1Q3 | 1/20 | 0.55 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.55 |
| ▸ | MACROD1 | Q9BQ69 | 1/20 | 0.55 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.55 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.55 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31229395 | 1.00 | P2RX3 (0.61) | P2RX3P2RX1P2RX2P2RX4P2RY1 | |
| SCHEMBL23978230 | 1.00 | P2RX3 (0.61) | P2RX3P2RX1P2RX2P2RX4P2RY1 | |
| Dda-Triphosphate SCHEMBL30586994 | 0.99 | P2RX3 (0.63) | P2RX3P2RX1P2RX2P2RX4P2RY1 | |
| Dda-Triphosphate SCHEMBL79815 | 0.99 | P2RX3 (0.63) | P2RX3P2RX1P2RX2P2RX4P2RY1 | |
| Dda-Triphosphate SCHEMBL30301198 | 0.99 | P2RX3 (0.63) | P2RX3P2RX1P2RX2P2RX4P2RY1 | |
| Dda-Triphosphate SCHEMBL24767736 | 0.99 | P2RX3 (0.63) | P2RX3P2RX1P2RX2P2RX4P2RY1 | |
| SCHEMBL8630966 | 0.99 | P2RX3 (0.63) | P2RX3P2RX1P2RX2P2RX4P2RY1 | |
| Dda-Triphosphate SCHEMBL23978346 | 0.99 | P2RX3 (0.63) | P2RX3P2RX1P2RX2P2RX4P2RY1 | |
| Dda-Triphosphate SCHEMBL12932305 | 0.99 | P2RX3 (0.63) | P2RX3P2RX1P2RX2P2RX4P2RY1 | |
| SCHEMBL12932333 | 0.93 | POLB (0.56) | P2RX3P2RX1P2RX2P2RX4P2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1240355-B1 | REMOVAL OF DYE-LABELED DIDEOXY TERMINATORS FROM DNA SEQUENCING REACTIONS | CAMBREX BIO SCIENCE ROCKLAND I (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-1240355-A4 | REMOVAL OF DYE-LABELED DIDEOXY TERMINATORS FROM DNA SEQUENCING REACTIONS | PROLINX INC (US) | 2004-12-08 | — | — | EP | disclosed |
| US-6818760-B1 | COMPRISES ADSORBING UNINCORPORATED MOLECULES INTO POROUS HYDROPHOBIC PARTICLES ENCAPSULATED IN A HYDROPHILIC MATRIX; KITS | PROLINX INCORPORATED | 2004-11-16 | — | — | US | disclosed |
| US-6599887-B2 | Aids, herpes virus | CHIMERIX, INC. | 2003-07-29 | — | — | US | disclosed |
| EP-1240355-A1 | REMOVAL OF DYE-LABELED DIDEOXY TERMINATORS FROM DNA SEQUENCING REACTIONS | PROLINX, INC. (US) | 2002-09-18 | — | — | EP | disclosed |
| US-6448392-B1 | LIPID, ESPECIALLY PHOSPHOLIPID, DERIVATIVES OF MODIFIED ANTIVIRAL NUCLEOSIDE ANALOGUES CAN BE INTEGRATED INTO STRUCTURE OF LIPOSOMES, FORMING STABLE LIPOSOMAL COMPLEX, DELIVER GREATER AMOUNTS OF DRUGS TO CELLS WITH LESS TOXICITY | CHIMERIX, INC. | 2002-09-10 | — | — | US | disclosed |
| US-6414136-B1 | ADSORPTION OF FLUORESCENT DYE-LABELED MOLECULES NOT INCORPORATED IN POLYMER ONTO HYDROPHOBIC MATERIAL AFTER PASSING THROUGH HYDROPHILIC MATRIX | PROLINX, INC. | 2002-07-02 | — | — | US | disclosed |
| US-20010033862-A1 | Methods of treating viral infections using antiviral liponucleotides | HOSTETLER KARL Y (US) | 2001-10-25 | — | — | US | disclosed |
| US-6252060-B1 | COMPLEX CONTAINING DIDEOXYGUANOSINE | NEXSTAR PHARMACEUTICALS, INC. | 2001-06-26 | — | — | US | disclosed |
| WO-2001025491-A1 | REMOVAL OF DYE-LABELED DIDEOXY TERMINATORS FROM DNA SEQUENCING REACTIONS | PROLINX, INC. (US) | 2001-04-12 | — | — | WO | disclosed |
| WO-2001025490-A1 | REMOVAL OF DYE-LABELED DIDEOXY TERMINATORS FROM DNA SEQUENCING REACTIONS | PROLINX, INC. (US) | 2001-04-12 | — | — | WO | disclosed |
| EP-0350287-B1 | Lipid derivatives of antiviral nucleosides, liposomal incorporation and method of use | CHIMERIX INC (US) | 2000-09-27 | — | — | EP | disclosed |
| US-5817638-A | USING HYBRID NUCLEOSIDES | NEXSTAR PHARMACEUTICALS, INC. (US) | 1998-10-06 | — | — | US | disclosed |
| EP-0594677-A4 | ANTIVIRAL LIPONUCLEOSIDES: TREATMENT OF HEPATITIS B | VICAL INC (US) | 1997-09-17 | — | — | EP | disclosed |
| EP-0594677-A1 | ANTIVIRAL LIPONUCLEOSIDES: TREATMENT OF HEPATITIS B | NeXstar Pharmaceuticals, Inc. (US) | 1994-05-04 | — | — | EP | disclosed |
| US-5223263-A | Viricide complex; aids therapy | VICAL, INC. (US) | 1993-06-29 | — | — | US | disclosed |
| WO-1993000910-A1 | ANTIVIRAL LIPONUCLEOSIDES: TREATMENT OF HEPATITIS B | VICAL, INC. (US) | 1993-01-21 | — | — | WO | disclosed |
| WO-1990000555-A1 | LIPID DERIVATIVES OF ANTIVIRAL NUCLEOSIDES, LIPOSOMAL INCORPORATION AND METHOD OF USE | VICAL, INC. (US) | 1990-01-25 | — | — | WO | disclosed |
| EP-0350287-A2 | Lipid derivatives of antiviral nucleosides, liposomal incorporation and method of use | NeXstar Pharmaceuticals, Inc. (US) | 1990-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010033862-A1 | Methods of treating viral infections using antiviral liponucleotides | PHOSPHO1, TK1, TYMP | P2RX3 1523/4885P2RX1 1434/4885P2RX2 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.